Biota, together with Indian and Israeli partners, has a long-term vision of strategic operations in India.

Biota plans to penetrate the Indian market as the Indian pharmaceutical industry has seen a massive expansion over the last few years, aiming at becoming a major player among global leaders in biopharmaceuticals and specialty generics.

Biota’s Indian Patent 567875, issued on 25 June 2025, expiry on November 2040, ensure a broad patent protection for advanced oral filmstrips comprising high-dosage hydrophobic bioactive ingredients.

We aim to cooperate with Indian pharmaceutical companies, towards development and commercialization of effective and safe oral filmstrips for treatment and prevention of, among other, diabetes/obesity, and neurological diseases.

Empagliflozin oral filmstrips for treatment of Type 2 Diabetes (T2D) is one of our leading product candidates.
Empagliflozin causes moderate reductions in blood pressure and body weight, due to excretion of glucose in the urine.

Biota is actively seeking cooperation with industry, and welcomes cooperation enquiries.

Link: Innovation | IPA India